Brief: Can-Fite Reports 2022 Financial Results & Provides Clinical Update

Can Fite Biopharma

30/03/2023 12:33

March 30 (Reuters) - Can Fite Biopharma Ltd  CANF.TA :
    * CAN-FITE REPORTS 2022 FINANCIAL RESULTS & PROVIDES
CLINICAL
UPDATE
    * CAN FITE BIOPHARMA LTD - AS OF DEC 31, 2022, HAD CASH,
CASH
EQUIVALENTS, AND SHORT-TERM DEPOSITS OF $7.97 MILLION
    * CAN FITE BIOPHARMA LTD - FY NET LOSS WAS $10.17 MILLION
VERSUS
NET LOSS OF $12.61 MILLION
    * CAN FITE BIOPHARMA: NAMODENOSON IS SHOWING POTENTIAL FOR
EFFICACY ACROSS SEVERAL INDICATIONS FROM LIVER DISEASE TO
PANCREATIC CANCER

Source text for Eikon:  ID:nBw306Ymwa 
Further company coverage:  CANF.TA 

 ((Reuters.Briefs@thomsonreuters.com;))